US 12,394,612 B2
Determination of antidepressants by mass spectrometry
Anita Dermartirosian, Stevenson Ranch, CA (US); Edith Shahbol, Northridge, CA (US); Karin Thomassian, Tujunga, CA (US); Shaun Rezaei, Santa Clarita, CA (US); and Asad Shah, Sylmar, CA (US)
Assigned to Quest Diagnostics Investments LLC, Secaucus, NJ (US)
Filed by Quest Diagnostics Investments LLC, Secaucus, NJ (US)
Filed on Dec. 18, 2023, as Appl. No. 18/543,524.
Application 18/543,524 is a continuation of application No. 16/887,298, filed on May 29, 2020, granted, now 11,887,828.
Claims priority of provisional application 62/855,863, filed on May 31, 2019.
Prior Publication US 2024/0120188 A1, Apr. 11, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. H01J 49/00 (2006.01); G01N 30/72 (2006.01); G01N 33/493 (2006.01)
CPC H01J 49/004 (2013.01) [G01N 30/7233 (2013.01); G01N 33/493 (2013.01)] 16 Claims
OG exemplary drawing
 
1. A method for simultaneously detecting or determining an amount of duloxetine, fluoxetine, and norfluoxetine in a biological sample by tandem mass spectrometry, the method comprising:
subjecting a biological sample to ionization under conditions suitable to produce one or more ions detectable by mass spectrometry;
determining the amount of one or more ions by tandem mass spectrometry, wherein the one or more ions comprise a norfluoxetine fragment ion with a mass-to-charge (m/z) ratio of 30.1±0.2; and
using the amount of the one or more ions to determine the amount of duloxetine, fluoxetine, and norfluoxetine in the biological sample.